Antigen Express gets notice of allowance for AE37 cancer vaccine
AE37 is currently under a randomized and controlled Phase II efficacy study in patients treated for breast cancer who are at high risk of recurrence. Favorable results from
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.
Gemcitabine HCI for Injection, the generic version of Gemcitabine HCI, was launched pursuant to a commercialization, manufacture and supply agreement signed by AstraZeneca and Taj Pharmaceuticals, indiacompanynews.com reported.
The companies will collaborate to advance-to-market an RNAi-based therapy for the treatment of non-muscle invasive bladder cancer. Debiopharm will shoulder full responsibility for the development and commercialization of